Niall T. Prendergast

Niall T. Prendergast

Auto-generated profile, based on publicly available information

Niall T. Prendergast

Division of Pulmonary, Allergy, Critical Care and Sleep Medicine; Department of Medicine; University of Pittsburgh School of Medicine; Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in CHEST Critical Care
Verified
Journal Article
Open access
MLMichael Lu
Michael Lu
CDCallie Drohan
Callie Drohan
WBWilliam Bain
William Bain
FSFaraaz A. Shah
Faraaz A. Shah
MBMatthew Bittner
Matthew Bittner
GKGeorgios D. Kitsios
Georgios D. Kitsios
Hospitalized patients with severe COVID-19 follow heterogeneous clinical trajectories, requiring different levels of respiratory support and experiencing diverse clinical outcomes. Differences in host immune responses to SARS-CoV-2 infection may account for the heterogeneous clinical course, but we have limited data on the dynamic evolution of systemic biomarkers and related subphenotypes. Improved understanding of the dynamic transitions of host subphenotypes in COVID-19 may allow for improved patient selection for targeted therapies. We examined the trajectories of host-response profiles in severe COVID-19 and evaluated their prognostic impact on clinical outcomes. In this prospective observational study, we enrolled 323 inpatients with COVID-19 receiving different levels of baseline respiratory support: (1) low-flow oxygen (37%), (2) noninvasive ventilation (NIV) or high-flow oxygen (HFO; 29%), (3) invasive mechanical ventilation (27%), and (4) extracorporeal membrane oxygenation (7%). We collected plasma samples on enrollment and at days 5 and 10 to measure host-response biomarkers. We classified patients by inflammatory subphenotypes using two validated predictive models. We examined clinical, biomarker, and subphenotype trajectories and outcomes during hospitalization. IL-6, procalcitonin, and angiopoietin 2 persistently were elevated in patients receiving higher levels of respiratory support, whereas soluble receptor of advanced glycation end products (sRAGE) levels displayed the inverse pattern. Patients receiving NIV or HFO at baseline showed the most dynamic clinical trajectory, with 24% eventually requiring intubation and exhibiting worse 60-day mortality than patients receiving invasive mechanical ventilation at baseline (67% vs 35%; P < .0001). sRAGE levels predicted NIV failure and worse 60-day mortality for patients receiving NIV or HFO, whereas IL-6 levels were predictive in all patients regardless of level of support (P < .01). Patients classified to a hyperinflammatory subphenotype at baseline (< 10%) showed worse 60-day survival (P < .0001) and 50% of them remained classified as hyperinflammatory at 5 days after enrollment. Longitudinal study of the systemic host response in COVID-19 revealed substantial and predictive interindividual variability influenced by baseline levels of respiratory support.

26 October 2022 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
NPNiall T. Prendergast
Niall T. Prendergast
COChukwudi A. Onyemekwu
Chukwudi A. Onyemekwu
KPKelly M. Potter
Kelly M. Potter
PTPerry J. Tiberio
Perry J. Tiberio
ATAlison E. Turnbull
Alison E. Turnbull
TGTimothy D. Girard
Timothy D. Girard
Importance: Agitation is common in mechanically ventilated ICU patients, but little is known about physician attitudes regarding agitation in this setting. Objectives: To characterize physician attitudes regarding agitation in mechanically ventilated ICU patients. Design, Setting, and Participants: We surveyed critical care physicians within a multicenter health system in Western Pennsylvania, assessing attitudes regarding agitation during mechanical ventilation and use of and confidence in agitation management options. We used quantitative clinical vignettes to determine whether agitation influences confidence regarding readiness for extubation. We sent our survey to 332 critical care physicians, of whom 80 (24%) responded and 69 were eligible (had cared for a mechanically ventilated patient in the preceding three months). Main Outcomes and Measures: Respondent confidence in patient readiness for extubation (0–100%, continuous) and frequency of use and confidence in management options (1–5, Likert). Results: Of 69 eligible responders, 61 (88%) agreed agitation is common and 49 (71%) agreed agitation is a barrier to extubation, but only 27 (39%) agreed their approach to agitation is evidence-based. Attitudes regarding agitation did not differ much by practice setting or physician demographics, though respondents working in medical ICUs were more likely ( P = .04) and respondents trained in surgery or emergency medicine were less likely ( P = .03) than others to indicate that agitation is an extubation barrier. Fifty-three (77%) respondents reported they frequently use non-pharmacologic measures to treat agitation, and 42 (70%) of those who reported they used non-pharmacologic measures during the prior 3 months indicated confidence in their effectiveness. In responses to clinical vignettes, confidence in patient's readiness for extubation was significantly lower if the patient was agitated ( P < .001) or tachypneic ( P < .001), but the presence of both agitation and tachypnea did not reduce confidence compared with tachypnea alone ( P = .24). Conclusions and Relevance: Most critical care physicians consider agitation during mechanical ventilation a common problem and agreed that agitation is a barrier to extubation. Treatment practice varies widely.

31 December 2025 in Journal of Critical Care
Verified
Journal Article
Open access
NPNiall T. Prendergast
Niall T. Prendergast
COChukwudi A. Onyemekwu
Chukwudi A. Onyemekwu
KTKelly M. Toth
Kelly M. Toth
CFChristopher A. Franz
Christopher A. Franz
GKGeorgios D. Kitsios
Georgios D. Kitsios
TGTimothy D. Girard
Timothy D. Girard
To derive and validate a simple, transparent model that quantifies risk for sedative-associated delirium in mechanically ventilated ICU patients, which could be used to guide decisions about personalized sedation. We performed backward stepwise logistic regression to derive a model predictive of sedative-associated delirium. We validated this model internally using hundredfold bootstrapping. We then validated this model externally in a separate prospective cohort of mechanically ventilated ICU patients. Five US hospitals, including one academic, one private, and three veterans hospitals. The parent cohort consisted of 1040 patients with either septic or cardiogenic shock, acute respiratory failure, or both. From the parent cohort 836 patients who received mechanical ventilation were selected to comprise the derivation cohort. None. Backwards stepwise regression produced a model with age, BMI, sepsis, SOFA, malignancy, COPD, sex, and doses of opioids, propofol, and benzodiazepines as predictors of sedative-associated delirium. The model had very good discriminative power, with an area under the receiver-operator curve (AUROC) of 0.83. Internal validation via bootstrapping showed preserved discriminatory function with an AUROC of 0.81 and graphical evidence of good calibration. External validation in a separate set of 340 patients showed good discrimination, with AUROC of 0.70. Risk for sedative-associated delirium during acute respiratory failure requiring mechanical ventilation can be quantified using a simple, transparent model, which can now be validated in a prospective study.

27 April 2024 in CHEST Critical Care
Verified
Journal Article
Open access
COChukwudi A. Onyemekwu
Chukwudi A. Onyemekwu
NPNiall T. Prendergast
Niall T. Prendergast
KPKelly M. Potter
Kelly M. Potter
NTNicole A. Toney
Nicole A. Toney
Seyed NouraieSeyed Nouraie
Seyed Nouraie
TGTimothy D. Girard
Timothy D. Girard
Acute brain dysfunction during sepsis, which manifests as delirium or coma, is common and is associated with multiple adverse outcomes, including longer periods of mechanical ventilation, prolonged hospital stays, and increased mortality. Delirium and coma during sepsis may be manifestations of alteration in systemic metabolism. Because access to brain mitochondria is a limiting factor, measurement of peripheral platelet bioenergetics offers a potential opportunity to understand metabolic changes associated with acute brain dysfunction during sepsis. Are altered platelet mitochondrial bioenergetics associated with acute brain dysfunction during sepsis? We assessed participants with critical illness in the ICU for the presence of delirium or coma via validated assessment measures. Blood samples were collected and processed to isolate and measure platelet mitochondrial oxygen consumption. We used Seahorse extracellular flux to measure directly baseline, proton leak, maximal oxygen consumption rate, and extracellular acidification rate. We calculated adenosine triphosphate-linked, spare respiratory capacity, and nonmitochondrial oxygen consumption rate from the measured values. Maximum oxygen consumption was highest in patients with coma, as was spare respiratory capacity and extracellular acidification rate in unadjusted analysis. After adjusting for age, sedation, modified Sequential Organ Failure Assessment score without the neurologic component, and preexisting cognitive function, increased spare respiratory capacity remained associated with coma. Delirium was not associated with any platelet mitochondrial bioenergetics. In this single-center exploratory prospective cohort study, we found that increased platelet mitochondrial spare respiratory capacity was associated with coma in patients with sepsis. Future studies powered to determine any relationship between delirium and mitochondrial respiration bioenergetics are needed.

1 September 2024 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
NPNiall T. Prendergast
Niall T. Prendergast
CFChristopher A. Franz
Christopher A. Franz
CSCaitlin Schaefer
Caitlin Schaefer
NCNicole Bensen Covell
Nicole Bensen Covell
KBKelsey Balish
Kelsey Balish
TGTimothy D. Girard
Timothy D. Girard

24 March 2025 in Critical Care Explorations
Verified
Journal Article
Open access
CHCole E. Hansell
Cole E. Hansell
HAHamam A. Aneis
Hamam A. Aneis
GKGeorgios D. Kitsios
Georgios D. Kitsios
WBWilliam G. Bain
William G. Bain
YZYanwu Bs Zhao
Yanwu Bs Zhao
FSFaraaz Shah
Faraaz Shah
OBJECTIVES: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) have therapeutic effects in diabetes mellitus. Prior clinical studies suggest incretins are prognostic of adverse outcomes in critical illness. We investigated whether incretin levels indicate disease severity and clinical outcomes in patients with acute respiratory failure, a common cause of critical illness. DESIGN: Retrospective cohort study. SETTING: ICUs in UPMC Health Systems hospitals within Western Pennsylvania. PATIENTS: Two hundred ninety-seven critically ill adults with acute respiratory failure. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We measured GLP-1 and GIP levels in baseline samples collected at the time of study enrollment. We compared incretin levels across subgroups differing by severity of illness and investigated associations between incretins and markers of systemic host responses and intestinal permeability. In our primary analysis, we tested the association of each incretin level with 90-day mortality by logistic regression in unadjusted analyses and in analyses adjusted for age, Sequential Organ Failure Assessment score, and circulating interleukin-6 levels. GLP-1 levels were higher in nonsurvivors and patients with or at-risk for acute respiratory distress syndrome compared to those intubated for airway protection. GLP-1 levels also positively correlated with systemic immune response biomarkers but not with markers of intestinal permeability. GLP-1 levels positively correlated with mortality in unadjusted (odds ratio, 1.99 [1.55–2.56]; p < 0.01) and adjusted (2.02 [1.23–3.31]; p < 0.01) analyses. GIP levels were not associated with mortality or with host response biomarkers. CONCLUSIONS: GLP-1 but not GIP levels were positively associated with systemic inflammation and mortality in critically ill patients with acute respiratory failure. Increased circulating GLP-1 levels may serve as prognostic biomarkers to identify patients who are likely to have worse outcomes.